Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Performance

BPTH opened at $0.84 on Wednesday. The stock’s 50 day simple moving average is $0.89 and its 200 day simple moving average is $1.08. Bio-Path has a 1 year low of $0.59 and a 1 year high of $9.99.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.